Literature DB >> 10974207

Extracellular accumulation of nitric oxide, hydrogen peroxide, and glutamate in astrocytic cultures following glutathione depletion, complex I inhibition, and/or lipopolysaccharide-induced activation.

K S McNaught1, P Jenner.   

Abstract

Dopaminergic neuronal death in substantia nigra in Parkinson's disease is accompanied by depletion of reduced glutathione levels and inhibition of complex I activity which occur partially in normal or activated cells. The relationship between neuronal death and altered glial function is not known, but this may involve the release of toxic mediators from astrocytes and microglia, which in turn cause neuronal injury. We have examined the effects of (l)-buthionine-[S,R]-sulfoximine ((l)-BSO)-induced glutathione depletion, inhibition of complex I activity by 1-methyl-4-phenylpyridinium (MPR(+)), and/or lipopolysaccharide (LPS)-induced activation on the extracellular accumulation of nitric oxide (NO), hydrogen peroxide (H(2)O(2)), and glutamate in primary cultures of rat forebrain astrocytes. Depletion of glutathione levels by up to 90% did not alter NO, H(2)O(2), or glutamate levels in cultured astrocytes. Inhibition of complex I activity by up to 43% had no effect on extracellular NO accumulation, but increased H(2)O(2) and glutamate levels. LPS-induced activation of cultured astrocytes increased extracellular levels of NO, H(2)O(2), and glutamate. Extracellular accumulation of NO and H(2)O(2) caused by LPS was markedly less in glutathione-depleted or complex I-inhibited astrocytic cultures compared to normal astrocytic cultures. In conclusion, complex I inhibition or activation of glial cells, alone or in combination with glutathione depletion, results in the extracellular accumulation of glutamate and the formation of NO and H(2)O(2), which in turn may form highly toxic peroxynitrite and hydroxyl radicals. Thus, altered glial function leading to oxidative stress and excitotoxicity may contribute to the initiation or progression of neuronal death in substantia nigra in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10974207     DOI: 10.1016/s0006-2952(00)00415-9

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  18 in total

Review 1.  Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders.

Authors:  Mark P Mattson
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 3.843

Review 2.  A further update on the role of excitotoxicity in the pathogenesis of Parkinson's disease.

Authors:  Giulia Ambrosi; Silvia Cerri; Fabio Blandini
Journal:  J Neural Transm (Vienna)       Date:  2014-01-01       Impact factor: 3.575

3.  Effects of propofol on P2X7 receptors and the secretion of tumor necrosis factor-α in cultured astrocytes.

Authors:  Jia Liu; Xiao-Fei Gao; Wen Ni; Jin-Bao Li
Journal:  Clin Exp Med       Date:  2011-05-24       Impact factor: 3.984

Review 4.  Metabolic Dysfunction in Parkinson's Disease: Bioenergetics, Redox Homeostasis and Central Carbon Metabolism.

Authors:  Annadurai Anandhan; Maria S Jacome; Shulei Lei; Pablo Hernandez-Franco; Aglaia Pappa; Mihalis I Panayiotidis; Robert Powers; Rodrigo Franco
Journal:  Brain Res Bull       Date:  2017-03-21       Impact factor: 4.077

5.  Astroglial P2X7 receptor current density increased following long-term exposure to rotenone.

Authors:  Xiao-Fei Gao; Wei Wang; Qiang Yu; Geoffrey Burnstock; Zheng-Hua Xiang; Cheng He
Journal:  Purinergic Signal       Date:  2011-02-24       Impact factor: 3.765

6.  Inhibition of oxygen radical formation by methylene blue, aspirin, or alpha-lipoic acid, prevents bacterial-lipopolysaccharide-induced fever.

Authors:  Walter Riedel; Uwe Lang; Ulrich Oetjen; Ulrike Schlapp; Masaaki Shibata
Journal:  Mol Cell Biochem       Date:  2003-05       Impact factor: 3.396

Review 7.  Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease.

Authors:  Susan Duty
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

8.  Effects of perinatal lipopolysaccharide (LPS) exposure on the developing rat brain; modeling the effect of maternal infection on the developing human CNS.

Authors:  M Xu; Z L Sulkowski; P Parekh; A Khan; T Chen; S Midha; T Iwasaki; N Shimokawa; N Koibuchi; A M Zavacki; E M Sajdel-Sulkowska
Journal:  Cerebellum       Date:  2013-08       Impact factor: 3.847

Review 9.  Altered neuronal-glial signaling in glutamatergic transmission as a unifying mechanism in chronic pain and mental fatigue.

Authors:  Elisabeth Hansson; Lars Rönnbäck
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

Review 10.  The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery.

Authors:  Garima Dutta; Ping Zhang; Bin Liu
Journal:  Fundam Clin Pharmacol       Date:  2008-08-15       Impact factor: 2.748

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.